Reports Q3 revenue $67.8M, consensus $57.69M. “We are pleased to report continued strong momentum through the first nine months of the year,” stated CEO Peter Greenleaf. “Going forward, our streamlined organization will enable us to lean further into key areas of the commercial LUPKYNIS business that have historically delivered optimal returns, while at the same time accelerating the development of our important pipeline product, AUR200.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- AUPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024
- Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan
- Aurinia Pharmaceuticals announces Japan MHLW approval for voclosporin
- Aurinia Pharmaceuticals Announces Board Restructuring and Director Changes